Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 6/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 6/20 | 0.41 |
| ▸ | DAO | P14920 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | RHEB | Q15382 | 2/20 | 0.39 |
| ▸ | CYP26A1 | O43174 | 2/20 | 0.38 |
| ▸ | F7 | P08709 | 1/20 | 0.38 |
| ▸ | F3 | P13726 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1003853 | 0.88 | DDB1 (0.44) | ESR1ESR2DAOCYP26A1KDM4E | |
| SCHEMBL12777445 | 0.88 | DDB1 (0.44) | ESR1ESR2DAOCYP26A1KDM4E | |
| SCHEMBL1006811 | 0.88 | KDM4A (0.37) | ESR1ESR2CYP26A1 | |
| SCHEMBL1003668 | 0.87 | ESR1 (0.38) | ESR1ESR2RHEBCYP26A1 | |
| SCHEMBL1007006 | 0.87 | ESR1 (0.38) | ESR1ESR2TSHRCYP26A1LMNA | |
| SCHEMBL1004610 | 0.87 | GRM2 (0.39) | ESR1ESR2RHEB | |
| SCHEMBL1006240 | 0.86 | PTGS1 (0.42) | ESR1ESR2CYP26A1KMT2A | |
| SCHEMBL1005137 | 0.86 | ESR1 (0.42) | ESR1ESR2LMNAMEN1KMT2A | |
| SCHEMBL1006534 | 0.86 | CYP26A1 (0.46) | ESR1ESR2TSHRRHEBCYP26A1 | |
| SCHEMBL1004177 | 0.85 | MAPT (0.38) | ESR1ESR2LMNAKDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7902252-B2 | Inhibitors of D-amino acid oxidase | SEPRACOR, INC. (US) | 2011-03-08 | — | — | US | disclosed |
| US-7902252-B2 | Inhibitors of D-amino acid oxidase | SEPRACOR, INC. (US) | 2011-03-08 | — | — | US | disclosed |
| US-7902252-B2 | Inhibitors of D-amino acid oxidase | SEPRACOR, INC. (US) | 2011-03-08 | — | — | US | disclosed |
| WO-2011011330-A2 | INHIBITORS OF D-AMINO ACID OXIDASE | SEPRACOR INC. (US) | 2011-01-27 | — | — | WO | disclosed |
| WO-2011011330-A2 | INHIBITORS OF D-AMINO ACID OXIDASE | SEPRACOR INC. (US) | 2011-01-27 | — | — | WO | disclosed |
| US-20100029737-A1 | INHIBITORS OF D-AMINO ACID OXIDASE | SEPRACOR INC. (US) | 2010-02-04 | — | — | US | disclosed |
| US-20100029737-A1 | INHIBITORS OF D-AMINO ACID OXIDASE | SEPRACOR INC. (US) | 2010-02-04 | — | — | US | disclosed |
| US-20100029737-A1 | INHIBITORS OF D-AMINO ACID OXIDASE | SEPRACOR INC. (US) | 2010-02-04 | — | — | US | disclosed |
| US-20090099248-A1 | INHIBITORS OF D-AMINO ACID OXIDASE | SEPRACOR INC. (US) | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099248-A1 | INHIBITORS OF D-AMINO ACID OXIDASE | DDO, DAO, ACHE | ESR1 3231/4885ESR2 4183/4885DAO 2/4885 |
| US-20100029737-A1 | INHIBITORS OF D-AMINO ACID OXIDASE | DDO, DAO, ACHE | ESR1 3231/4885ESR2 4183/4885DAO 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.